The OxyLo Team
Our Story
OxyLo is a San Diego based Biotechnology company. We focus on helping liver patients get their life back. Our patented capsule technology is a revolutionary biomaterial-based implant designed to convert safe prodrugs into active chemotherapies from the inside of a tumor. Our mission is to starve these tumors to give hope and time back to patients who need it most.
We are a team of international PhD scientists with a combined 40 years of experience working in biology, chemistry, and engineering. Our philosophy of focusing on creativity and interdisciplinary science has led to the breakthrough innovations that we aim to provide today.
Core management team
Scientific Advisors
Isabel Newton, M.D., Ph.D. Interventional Radiologist
Tom Molley, PhD Chief Executive Officer
& Co-founder
Biomaterials scientist and previous UC San Diego postdoc who developed the local enzyme microcapsule capsule technology during his PhD.
Rebekah white, MD, FACS Surgical Oncologist
Kristopher Kilian, PhD Chief Scientific Advisor
& Co-founder
Professor and co-Director of the Australian Centre for NanoMedicine who’s research focuses on the development of model extracellular matrices and dynamic biomaterials
James Mackay, PhD
CEO of Crystalys
Erin LaMontagne, PhD VP of Research & Development
Bioengineer with deep experience in biomaterials, microfluidic systems, stem cell–derived tissue models, and translational platform development across academic and industry settings.
Paul Grint, MD
CEO of CodaGEnix
Mike Hoerres, MS
CEO at Aquinas Life Sciences
